Skip to content
Open access

Cognitive Workload and Its Relationship with Neurocognitive Performance Before and After Breast Cancer Chemotherapy

Aug 2026 · Journal of the International Neuropsychological Society · pp. 1 - 9 · 0 citations · 43 references
Medicine

Abstract

Objective: To compare associations between neurocognitive testing and two different self-report paradigms: 1) recall-based (PROMIS Cognitive Function); and 2) real-time, task-specific (NASA-Task Load Index [NASA-TLX]) among 56 patients with breast cancer. Method: This is a secondary analysis from a phase II, single-arm trial of memantine to prevent cognitive decline among patients receiving chemotherapy for breast cancer (NCT04033419). Before chemotherapy and 4 weeks after their final cycle, participants completed neuropsychological assessment and self-report measures. Memantine was administered between assessments. At pre-chemotherapy, multivariable linear regression evaluated associations between a unit-weighted, composite neurocognitive test score with PROMIS Cognitive Function and NASA-TLX, controlling for age, cancer stage, and cognitive reserve. Explanatory analyses examined associations within individual neurocognitive subtests. Multivariable regression explored the extent to which pre-treatment self-reported cognition predicted post-treatment performance. Results: Pre-chemotherapy, higher NASA-TLX scores (greater perceived workload) were robustly associated with worse performance (β = −0.31 [−0.50, −0.12], p = .002). Relationships were strongest for executive function: Animal Fluency (IQR = 35): −3.3 (−5.8, −0.8), p = .011; COWA (IQR = 36) = −6.7 (−12.8, −0.7), p = .031; One Touch Stockings (IQR = 31): −0.70 (−1.0, −0.3), p <.001. Pre-treatment NASA-TLX was also associated with post-treatment performance in univariable but not multivariable models. PROMIS Cognitive Function and neurocognitive performance were not associated. Conclusions: The NASA-TLX and neurocognitive performance were strongly associated, particularly in the executive function domain. Future work involving the NASA-TLX in cancer populations, including its use in everyday contexts, will help clarify whether it may enhance CRCI characterization.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.